Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.
Kambhampati S, Saumoy M, Schneider Y, Pak S, Budde LE, Mei MG, Siddiqi T, Popplewell LL, Wen YP, Zain J, Forman SJ, Kwak LW, Rosen ST, Danilov AV, Herrera AF, Thiruvengadam NR.
Kambhampati S, et al. Among authors: wen yp.
Blood. 2022 Dec 22;140(25):2697-2708. doi: 10.1182/blood.2022016624.
Blood. 2022.
PMID: 35700381
Free PMC article.